Healthy hair doesn’t just happen—it’s the result of consistent care, the right products, and a nutrient-rich routine. While shampooing and conditioning are important, they aren’t enough to keep hair strong, shiny, and resilient over time. Environmental stressors, heat styling, chemical treatments, and even seasonal changes can damage your strands and scalp. To restore moisture, strengthen roots, and promote hair growth, adding the best hair oils for healthy hair to your routine is essential.
Hair oils are natural emollients that nourish both the scalp and hair shaft. These oils are packed with vitamins, fatty acids, antioxidants, and other nutrients that protect and revitalize your hair from the inside out. Whether you’re battling frizz, split ends, dryness, or hair fall, the right hair oil can be a game-changer.
Using hair oil regularly can deeply hydrate your hair, reduce protein loss, prevent breakage, and add long-lasting shine. Some oils even improve scalp circulation, which stimulates hair follicles and encourages faster growth. Others have antifungal and antibacterial properties that soothe scalp irritation and prevent dandruff.
With countless oils on the market, it can be difficult to choose the right one. That’s why we’ve compiled a list of the best hair oils for healthy hair, each carefully selected for their proven benefits and versatility. These five oils work across various hair types and concerns—from dry and damaged strands to thinning and oily scalps.
In this article, you’ll discover how these natural oils can transform your hair, how to use them effectively, and which one is best for your unique needs. Keep reading to find out how to get soft, strong, and shiny hair—naturally.
1. Argan Oil: The Ultimate Moisturizer
Often referred to as “liquid gold,” argan oil is a powerhouse for dry, damaged hair. Rich in vitamin E, antioxidants, and essential fatty acids, this oil deeply hydrates hair and restores its natural shine. Argan oil also helps to smooth frizz and prevent split ends, making it ideal for those with coarse or curly hair. Regular use can improve hair texture, leaving it soft and manageable.
Benefits:
– Deeply hydrates and nourishes
– Reduces frizz and flyaways
– Repairs split ends and strengthens hair
Best for: Dry, damaged, and frizzy hair
2. Coconut Oil: A Natural Hair Strengthener
Coconut oil is a classic favorite for hair care. Packed with vitamins and fatty acids, coconut oil penetrates deep into the hair shaft to provide long-lasting moisture. It’s known for its ability to reduce protein loss in hair, which helps prevent breakage and split ends. Coconut oil also has antimicrobial properties that can keep your scalp healthy and free from dandruff or infections.
Benefits:
– Strengthens hair and prevents breakage
– Moisturizes and nourishes the scalp
– Prevents dandruff and scalp infections
Best for: Dry, brittle hair and sensitive scalps
3. Jojoba Oil: A Scalp-Friendly Solution
Jojoba oil is incredibly similar to the natural oils produced by your scalp, making it an excellent choice for hair care. This lightweight oil balances sebum production, making it suitable for both dry and oily scalps. Jojoba oil helps unclog hair follicles, promoting healthy hair growth while preventing dandruff and flakiness. It also adds shine and smoothness to hair without weighing it down.
Benefits:
– Balances oil production on the scalp
– Promotes healthy hair growth
– Moisturizes without greasiness
Best for: Oily scalps, dry ends, and preventing hair thinning
4. Castor Oil: A Remedy for Hair Growth
If you’re looking to boost hair growth, castor oilis a must-try. Rich in ricinoleic acid, castor oil promotes blood circulation to the scalp, which can encourage hair growth. It’s also a potent moisturizer that helps prevent dryness and breakage. Castor oil has antibacterial and antifungal properties, making it effective in treating scalp infections that can hinder hair growth. However, because it is quite thick, it is often mixed with lighter oils, like coconut or jojoba oil, for easier application.
Benefits:
– Promotes hair growth
– Thickens and strengthens hair
– Fights scalp infections and dandruff
Best for: Hair thinning and scalp issues
5. Olive Oil: A Versatile Hair Nourisher
Olive oil has been used for centuries for its health benefits, both for the body and the hair. Packed with antioxidants and vitamin E, olive oil deeply nourishes the hair, repairing damage from within. It also provides a protective layer, shielding hair from environmental stressors. Olive oil is great for treating dry, over-processed hair, and it also helps with frizz control, giving your hair a glossy, polished look.
Benefits:
– Nourishes and repairs hair damage
– Adds shine and smoothness
– Protects hair from environmental damage
Best for: Dry, damaged, or frizzy hair
Selecting the best oil for your hair depends on your specific hair type and concerns. For deep hydration and frizz control, argan oil or coconut oil is a great choice. If you’re aiming to balance oil production and encourage hair growth, jojoba oil and castor oil are your go-to options. For all-around nourishment and protection, olive oil is a versatile, multi-benefit oil.
Remember to perform a patch test before applying any oil to your scalp or hair, especially if you have sensitive skin. With regular use, the right hair oil can transform your locks, leaving them shiny, healthy, and full of life.
India is witnessing a fresh COVID-19 surge in June 2025, with over 4,300 active cases and 7 new deaths. Rising infections in Delhi, UP, West Bengal, and Gujarat spark public health concerns amid the emergence of the NB.1.8.1 variant.
India’s COVID-19 Surge in June 2025: A Renewed Threat in 2025
India is once again grappling with a renewed rise in COVID-19 cases. As of early June 2025, over 4,300 active cases have been reported across the country, with seven fatalities registered in a 24-hour span. The states of Delhi, Uttar Pradesh, West Bengal, and Gujarat are seeing a noticeable uptick in new infections, prompting public health advisories and calls for renewed vigilance.
This unexpected rise comes after months of relatively low transmission, and the surge is being closely monitored by the Union Health Ministry, epidemiologists, and state governments. The emergence of the NB.1.8.1 Omicron subvariant, first identified in China, is believed to be a significant contributor to the new wave.
Current National Scenario: Tracking the Numbers
As of June 4, 2025:
Total active cases: 4,366
Daily increase in active cases: 276
Patients discharged in 24 hours: 3,281
New deaths: 7
While the absolute numbers are far from the peaks seen in earlier waves, the sharp upward trajectory is drawing concern, especially given the virus’s history of exponential spread.
State-Wise COVID-19 Spike: Delhi, UP, Bengal, and Gujarat on Alert
Delhi
New cases: 64
Active cases: 483
Hospitalizations: Rising gradually
Fatality: A 22-year-old woman with a history of TB and respiratory complications succumbed to COVID pneumonia
The Delhi government has urged citizens to wear masks in crowded places and has reintroduced screening protocols in some hospitals and educational institutions.
Uttar Pradesh’s healthcare officials have begun reactivating contingency plans for oxygen supply, emergency beds, and isolation facilities.
West Bengal
New infections: 60
Affected districts: Kolkata, Howrah, North 24 Parganas, and Darjeeling
Response: CM Mamata Banerjee held an emergency review meeting with health officials
With memories of the 2021 Delta wave still fresh in public consciousness, Bengal’s health infrastructure is being put on high alert.
Gujarat
New cases: 108
Active cases: 461
Hospitalization: 20 patients admitted; others under home isolation
Fatality: One death reported due to COVID-related complications
The Gujarat Health Department stated that over 70% of the new cases were infected with the NB.1.8.1 subvariant, detected via genome sequencing.
The NB.1.8.1 Subvariant: A New Player in the Pandemic
This Omicron offshoot is believed to be more transmissible and partially immune-evasive. Although not confirmed to cause more severe disease, its rapid spread has been flagged by global health bodies.
Key Characteristics
Transmissibility: Higher than previous Omicron subvariants
Severity: Mild to moderate, especially in vaccinated individuals
Immune Escape: Can partially bypass immunity from previous infection or vaccination
First detected: China, now reported in Southeast Asia and parts of the U.S.
According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), NB.1.8.1 is now present in over 10 Indian states.
Fatalities: Underlying Conditions Remain a Key Risk Factor
Among the seven reported COVID-related deaths:
4 in Maharashtra: Elderly patients with comorbidities like diabetes, COPD, and Parkinson’s
1 in Delhi: A young woman with past tuberculosis and COVID pneumonia
1 in Tamil Nadu: A 76-year-old man with ARDS and multi-organ failure
1 in Gujarat: Details awaited, but comorbid conditions likely
This pattern underscores that COVID-19 continues to be life-threatening for individuals with existing health vulnerabilities, even in the post-vaccination phase of the pandemic.
Hospital Readiness: Are We Prepared for Another Wave?
Hospital Admissions Rising
Several Tier-1 and Tier-2 city hospitals have reported a mild rise in admissions, particularly among the elderly and those with underlying diseases.
In cities like Delhi and Mumbai, private hospitals have begun setting aside dedicated COVID wards again.
Oxygen and ICU Preparedness
In anticipation of a further spike, states have started reviewing:
Oxygen stock levels
ICU bed availability
Ventilator readiness
Ambulance fleet coordination
Vaccination Update: How Immune is India?
India’s COVID vaccination campaign has slowed down significantly in 2024–25 due to pandemic fatigue and the perceived end of the emergency.
Vaccination Coverage (as of May 2025):
First dose: 95% of eligible adults
Second dose: 89%
Booster (precaution) dose: ~42% uptake
New variant-specific booster: Approved but not widely administered yet
The low booster uptake is a concern, especially with NB.1.8.1’s immune-evasive properties.
Public Health Advisory: Government Response So Far
The Ministry of Health and Family Welfare (MoHFW) has issued the following directives:
State-level genome sequencing intensification
Daily case monitoring and district-wise tracking
Stockpiling of antiviral drugs and PPE kits
Resumption of public awareness campaigns
No lockdown or curfew has been announced, but states have the autonomy to impose localized restrictions if necessary.
Expert Opinions: What Should Citizens Know?
Dr. Randeep Guleria, former AIIMS Director, has stated:
“The rise in cases is not unexpected given the emergence of a new variant. Most infections are mild, but vulnerable populations must exercise caution.”
Public health expert Dr. Anupam Sinha emphasized:
“We must not wait for the situation to spiral out of control. Preventive masking, testing, and vaccination are our best tools.”
Social Behavior: Are People Letting Their Guard Down?
Complacency Returns
After over two years of strict protocols, many people have:
Stopped wearing masks
Avoided booster doses
Resumed large gatherings without caution
In urban areas, malls, metros, and markets are once again crowded and largely mask-free, raising concerns about rapid community transmission.
Schools, Offices, and Public Spaces: Any New Guidelines?
Schools
No closures announced yet
Thermal screening resumed in Delhi and Gujarat schools
Online classes being prepared as backup
Workplaces
No return to mandatory WFH policies
Advisories issued for hybrid models and ventilation improvement
Travel and Transport
No fresh travel bans
Domestic flights continue normally
Passengers from high-risk areas are being screened at select airports
International Comparisons: Global Cases Also Rising
India is not alone. Many parts of the world—including China, Japan, and Southeast Asia—are experiencing minor surges in cases linked to new Omicron variants.
WHO’s Position
The World Health Organization has warned that COVID-19 is still a public health threat, despite global vaccination coverage and improved treatments.
The WHO recommends continued testing, global cooperation, and transparency in variant tracking.
Lessons from the Past: Avoiding Mistakes
India’s devastating second wave in 2021 taught hard lessons:
The importance of oxygen supply chains
Early warnings based on variant detection
Transparent case reporting
Health infrastructure readiness
Authorities and citizens alike are being reminded not to repeat the errors of delay and denial.
Looking Ahead: What Can Citizens Do?
Preventive Measures Still Matter
Mask up in crowded areas
Get the booster dose, especially the elderly
Avoid unnecessary travel to high-risk zones
Isolate if symptomatic
Get tested promptly
Digital Tools
The Aarogya Setu app is being updated with new alerts
State health portals are now sharing real-time case data again
Conclusion: A Time for Caution, Not Panic
India’s COVID-19 surge in June 2025 is a wake-up call. While the situation is under control for now, the potential for rapid spread remains. With new variants on the horizon, the emphasis must return to community-level precautions, state-level readiness, and scientific vigilance.
Every citizen has a role to play in ensuring that history does not repeat itself.
COVID-19 Resurgence in India: As of June 2, 2025, India is witnessing a concerning resurgence of COVID-19 infections, signaling what health experts fear could be the onset of another wave. According to the latest data released by the Union Ministry of Health and Family Welfare, the country has reported a total of 3,961 active COVID-19 cases, a significant rise compared to figures observed just a few weeks ago. While this number might appear moderate in comparison to the devastating peaks witnessed in 2020 and 2021, the current upward trend is being closely monitored by medical authorities and state governments alike, especially as the increase is not isolated to one region but is spread across multiple states including Kerala, Maharashtra, Delhi, Gujarat, West Bengal, and Karnataka.
This sudden surge in infections is being attributed to a combination of multiple factors. First and foremost is waning immunity among the population, especially those who received their last vaccine dose more than a year ago and have not taken a booster. While the national vaccination campaign succeeded in administering over two billion doses by mid-2023, recent trends indicate a plateau in booster shot uptake, particularly in rural and semi-urban areas. Experts warn that immunity—whether from vaccination or natural infection—tends to diminish over time, making individuals more susceptible to reinfection.
Secondly, there is a visible relaxation in public behavior and safety protocols. In most parts of India, mask mandates have been lifted, and COVID-appropriate behavior has all but vanished from everyday public life. Public transport systems are crowded, marketplaces are bustling, and large-scale weddings and social functions are being organized with minimal health precautions. The return to pre-pandemic normalcy, while welcome from an economic and social standpoint, is proving to be fertile ground for viral resurgence, especially in densely populated metros.
The third and perhaps most alarming contributor to the current spike is the emergence of new COVID-19 variants. As per recent findings from genomic sequencing labs across the country, a new subvariant of Omicron—NB.1.8.1—has been detected in several Indian states. While preliminary data suggest that this subvariant may not cause severe disease in most vaccinated individuals, it is believed to be highly transmissible, which explains the rapid increase in case numbers across geographically distant regions. The World Health Organization (WHO) has placed this variant under monitoring, and Indian epidemiologists are urging caution until further data becomes available.
COVID-19 Resurgence in India: State-Wise Overview of Rising Cases
Kerala, Maharashtra, and Delhi are emerging as major hotspots. Kerala currently leads in active case numbers, driven by urban clusters in cities like Thiruvananthapuram, Kochi, and Kozhikode. Maharashtra follows closely, with Mumbai and Pune showing increasing daily case counts. In Delhi, where public interactions remain high and mask usage has dropped significantly, the national capital has recorded over 82 COVID-related deaths since January 2025. Other states such as Gujarat, West Bengal, and Karnataka are witnessing early signs of escalation as well.
Ahmedabad recently reported its first COVID-related fatality of the year, a 47-year-old woman with multiple comorbidities. The incident has prompted Gujarat’s health department to review hospital preparedness and relaunch public awareness campaigns.
Hospitalizations and Public Health Preparedness
One of the more troubling aspects of this resurgence is the slow yet noticeable increase in hospital admissions. Although most new infections are reportedly mild or asymptomatic, hospitals in affected areas are seeing a rise in patients with breathing difficulties and pre-existing health issues.
In response, the Ministry of Health has advised all states and union territories to conduct mock drills, reassess oxygen supply systems, ensure availability of ICU beds, and maintain a steady stock of antiviral medications. Isolation wards, many of which had been dismantled or converted back to regular use, are being reactivated in anticipation of a further surge.
Several state governments are also initiating genome surveillance to track and trace the spread of NB.1.8.1 and other variants. Testing has been ramped up in high-density areas, with some localities in Mumbai, Delhi, and Kochi launching door-to-door screening for symptomatic individuals.
Vaccine Hesitancy and Booster Drive Challenges
Despite having an expansive vaccination program in place, India continues to face challenges in its booster dose campaign. Data from the CoWIN platform suggests that while initial two-dose coverage remains high, uptake of precautionary doses has stagnated at around 37% nationally. Among those over 60 years of age, this figure rises to just 53%, well below the desired target.
Vaccine hesitancy, particularly among rural populations and some tribal regions, is being fueled by misinformation, fatigue, and a sense of complacency. Public health officials are renewing efforts to address these issues through community outreach programs, localized mobile vaccination units, and partnerships with NGOs and faith-based organizations.
Variants Under Watch: The NB.1.8.1 Concern
The newly detected NB.1.8.1 subvariant is under close examination by both Indian and international health agencies. Early reports indicate it possesses a higher transmissibility rate than previous Omicron sublineages but has not yet demonstrated an increased ability to evade vaccine-induced immunity entirely. However, it is still too early to rule out future risks.
According to the Indian SARS-CoV-2 Genomics Consortium (INSACOG), at least 148 samples of NB.1.8.1 have been sequenced across six states. The mutation profile of this subvariant suggests enhanced spike protein changes that could improve receptor binding, a feature that made the original Omicron and Delta variants so widespread.
Government Measures and Policy Directives
So far, the central government has not announced any nationwide restrictions, but the Health Ministry has issued a fresh set of advisories. These include reinforcing mask use in public transport and indoor public spaces, avoiding large gatherings in high-case-load districts, and reintroducing thermal screening at airports and major railway stations.
States have also been asked to update their COVID-19 control plans and ensure all districts have an emergency response team on standby. Some urban local bodies in Kerala, Maharashtra, and West Bengal are revisiting containment zone strategies and have started localized lockdowns in apartment complexes and housing societies with cluster outbreaks.
Public Response and Media Awareness
The Indian public’s reaction to the current spike has been mixed. While some remain vigilant and are reinstating personal safety practices, many others express pandemic fatigue. Media outlets have ramped up coverage, emphasizing verified information and expert opinions to combat rising misinformation.
Social media platforms are being monitored more rigorously by the Ministry of Electronics and IT to flag and remove fake news about vaccine side effects or unfounded variant panic. Influencers, public figures, and local celebrities are being encouraged to spread awareness using multilingual messaging.
Conclusion: A Call for Renewed Vigilance
As India grapples with this fresh spike in COVID-19 cases, the coming weeks will prove crucial. The current situation, while not yet critical, is a reminder that the virus continues to evolve and that public health must remain a national priority. With the right mix of science-based policy, community awareness, and government readiness, India can contain the spread before it spirals into a full-blown wave.
Public cooperation remains key. Authorities urge citizens to get vaccinated, avoid misinformation, and adhere to basic safety norms. The COVID-19 pandemic may no longer dominate headlines daily, but its shadow still lingers—a silent warning that vigilance, not complacency, will shape the nation’s path forward.
Do Follow:
Ministry of Health and Family Welfare (MoHFW) – COVID-19 Dashboard This dashboard offers real-time data on COVID-19 cases across India, including state-wise statistics for West Bengal. 🔗 https://covid19dashboard.mohfw.gov.in/
Press Information Bureau (PIB) – COVID-19 Press Releases The PIB provides official press releases and updates from the Government of India regarding COVID-19, including information on new variants like JN.1. 🔗 https://www.pib.gov.in/PressReleseDetail.aspx?PRID=1987840
Integrated Disease Surveillance Programme (IDSP) – Ministry of Health and Family Welfare IDSP monitors disease outbreaks and provides alerts and updates, including those related to COVID-19. 🔗 https://idsp.mohfw.gov.in/
Indian Council of Medical Research (ICMR) ICMR conducts and disseminates research on various health issues, including COVID-19 variants and their impact. 🔗 https://www.icmr.gov.in/
INSACOG (Indian SARS-CoV-2 Genomics Consortium) INSACOG monitors the genomic variations in SARS-CoV-2, including tracking new variants like JN.1. 🔗 https://insacog.gov.in/
Government of West Bengal – Department of Health & Family Welfare The official portal provides state-specific health advisories, updates, and resources related to COVID-19. 🔗 https://www.wbhealth.gov.in/
Press Information Bureau (PIB) – COVID-19 Updates Regular bulletins and updates on the COVID-19 situation in India, including variant tracking and health advisories. 🔗 https://pib.gov.in/PressReleasePage.aspx?PRID=1778959
India COVID-19 Surge June 2025: Active Cases Reach 3,758 After Months of Stability
India has seen a sharp increase in COVID-19 infections, with active cases climbing to 3,758 as of June 1, 2025. This is the first major spike in several months, raising concerns among healthcare experts and the general public alike. According to the Ministry of Health and Family Welfare (MoHFW), 363 new cases were reported between Saturday and Sunday, indicating a noticeable resurgence of the virus in several states.
States With the Highest Active COVID-19 Cases: Kerala, Maharashtra, and Delhi Lead the Surge
The majority of the new COVID-19 cases are concentrated in three states—Kerala, Maharashtra, and Delhi. Kerala continues to report the highest number of active cases at 1,400. Maharashtra has 485 active infections, while Delhi has recorded 436. Over the past 24 hours, Kerala logged 64 new cases, Delhi reported 61, and Maharashtra added 18 to its tally. Health officials in these states have urged residents to remain cautious and follow COVID-19 safety protocols rigorously.
Two New COVID-19 Deaths Reported in India: Both Patients Had Severe Comorbid Conditions
In a tragic development, India reported two new COVID-19-related deaths in the past 24 hours. One occurred in Kerala and the other in Karnataka. In Kerala, a 24-year-old woman suffering from severe health issues like sepsis, hypertension, and decompensated chronic liver disease (DCLD) succumbed to the virus. Karnataka recorded the death of a 63-year-old man who had multiple underlying conditions, including Pulmonary TB and buccal mucosa squamous cell carcinoma. Both patients had tested positive for COVID-19 during routine checks related to their pre-existing health issues.
Karnataka Government Issues Fresh COVID-19 Advisory Urging Public to Adopt Preventive Measures
In response to the recent increase in infections, the Karnataka government has released a new public advisory. It emphasizes the importance of wearing masks, especially in crowded or enclosed public areas. Citizens are also advised to maintain physical distancing and adhere to proper hygiene practices. The advisory highlights the need to protect high-risk individuals, such as the elderly and those with chronic illnesses, to prevent further fatalities.
Delhi Confirms Its First COVID-19 Death Amid Latest Wave of Infections in June 2025
Delhi has also reported a COVID-19-related death, marking its first fatality during the ongoing spike in cases. According to officials, a 60-year-old woman who had recently undergone a laparotomy for acute intestinal obstruction tested positive for COVID-19. Although her death was attributed to complications from her underlying condition, the positive COVID-19 status has raised concerns about community transmission and the vulnerability of immunocompromised individuals.
Possible Causes Behind the COVID-19 Resurgence: New Variants and Reduced Public Vigilance
Health experts are pointing to the likely role of emerging sub-variants of the COVID-19 virus in driving the current surge. These variants may be more transmissible, allowing the virus to spread faster among communities. Additionally, the general relaxation in public safety measures such as mask-wearing, social distancing, and reduced vaccination follow-ups may have contributed to the rise in infections. Medical authorities are urging citizens to stay alert and avoid becoming complacent.
Government and Health Experts Urge Public to Follow Essential COVID-19 Safety Protocols
The Ministry of Health is strongly recommending that citizens return to basic safety protocols to curb the spread of the virus. This includes consistent use of face masks, especially in public transport and markets, frequent handwashing or sanitizing, and maintaining distance from those showing symptoms of respiratory illness. While there is no formal lockdown or travel restriction, local authorities may implement targeted restrictions if case numbers continue to climb.
Public Spaces, Workplaces, and Schools Advised to Reinforce COVID-19 Precautions Immediately
Workplaces, educational institutions, and public service departments across states have been urged to reintroduce standard COVID-19 precautions. This includes ensuring adequate ventilation, conducting regular temperature screenings, maintaining surface sanitation, and minimizing large gatherings. In schools, staff and students are being asked to wear masks, particularly in indoor classrooms and assembly halls.
What You Can Do Now: Simple Steps to Stay Safe Amid India COVID-19 Surge in June 2025
With the ongoing India COVID-19 surge in June 2025, public cooperation is more critical than ever. Here are simple but effective steps every individual should follow:
Mask up in crowded indoor settings like malls, public transport, and hospitals.
Wash hands frequently using soap or an alcohol-based sanitizer.
Avoid unnecessary travel if feeling unwell or experiencing symptoms like fever, cough, or fatigue.
Encourage vaccination and booster doses among family members and peers.
Consult a doctor immediately if you exhibit symptoms or have been in contact with a confirmed case.
Community Vigilance and Personal Responsibility Key to Combating the Current Surge
The India COVID-19 surge in June 2025 is a stark reminder that the pandemic is not yet over. While vaccines and improved healthcare systems have reduced the severity of most infections, the risk remains high for vulnerable populations. Health officials and state governments are closely monitoring the situation and are ready to implement additional measures if needed. Citizens must act responsibly and help reduce transmission through disciplined behavior.
Ministry of Food Processing Industries (MoFPI), in collaboration with the National Institute of Food Technology Entrepreneurship and Management (NIFTEM-Kundli), organized a one-day SWASTH workshop (Stakeholders Workshop on Actionable Strategies for Tackling HFSS and UPF). The workshop focused on “Shedding Light on Science, Consumption, and Choices in Modern Food.”
Keynote speakers at the Swasth Workshop
Delivering the keynote address, at the SWASTH workshop Dr. Subrata Gupta, Secretary, MoFPI, emphasized that in today’s fast-paced world, health and diet have become more important than ever. He noted a growing public consciousness around wellness, as evident from the increasing use of smart-watches to track daily physical activity. However, he pointed out a critical oversight: “While we keep track of how many steps we walk each day, we often fail to monitor how much energy or how many calories we consume every day.”
To address this gap, Dr. Gupta encouraged NIFTEM-K to lead the development of a smart watch-like device capable of measuring an individual’s daily calorie or energy intake. Referring to global health trends, he cited WHO and MCI data, which indicate that two-thirds of global deaths are caused by non-communicable diseases (NCDs). He also highlighted pressing concerns such as food adulteration in processed products and large-scale food wastage, and called for collective innovation and action to tackle these issues. Dr. Gupta also asked NIFTEM-K to organise these kind of events on regular basis.
Dr. Harinder Singh Oberoi, Director, NIFTEM-K in his welcome note at the swasth workshop, announced that the institute will soon propose the inclusion of chapters on food processing in NCERT textbooks. The initiative aims to educate children about healthy eating habits from a young age. Referencing traditional Indian wisdom, Dr. Oberoi remarked: “Food be the medicine,” echoing time-tested remedies passed down by grandmothers. He added that NIFTEM-K, in collaboration with FSSAI is willing to work actively to standardize and notify methodologies for determining added sugar in food products—bridging the gap between traditional knowledge and modern science.
Dr. Ravinarayan Acharya, DG, Central Council for Research in Ayurvedic Sciences(CCRAS), spoke on the traditional principles of Ayurveda during the swath workshop. Highlighting the ancient concept of “Hitam-Ahitam, Sukham-Dukham”, he noted that in Ayurveda, food itself is considered medicine. “The primary objective of Ayurveda is to maintain good health, while treating illness comes second,” he explained. Dr. Acharya also stated that the Ministry of Ayush is working closely with FSSAI, various central ministries, and state governments to ensure the safety, quality, and healthfulness of food products.
Dr. Satyen Panda, Executive Director (R&D) and Advisor (QA, FSSAI), addressed the risks associated with HFSS (High in Fat, Salt, and Sugar) and ultra-processed foods (UPFs). He noted that adulteration is widespread in many processed items and emphasized the need for a balanced and scientific approach to combat this growing concern effectively.
In the first technical session at the swasth workshop Dr. Priyanka Bansal, Sceintist-E, ICMR highlighted about the different guidelines issued by ICMR from time to time and also about different schemes of ICMR for anaemia, addressing nutrient deficiency etc. Mr. Ashim Sanyal, CEO of Consumer VOICE, emphasized the urgent need to define HFSS in the Indian context and advocated for the accelerated adoption of scientifically validated Nutrient Profiling Models (NPMs) tailored to national dietary and public health needs and earliest implementation of FoPNL.
The second session, of the swasth workshop titled “Science Beyond HFSS and UPF: Presentation of FAQs”, was led by experts from academia and research. Dr. Komal Chauhan, Dean (Research), NIFTEM-K, highlighted that the blanket assumption that all processed foods are harmful is incorrect and called for nuanced, evidence-based discussions.
Dr. Heena Yadav, Asst. Prof., NIFTEM-K presented a comprehensive FAQ document on HFSS and UPF, elaborating on the NOVA classification system and outlined the next steps, including wider consultations and submission of the report to the MoFPI. Adding to the academic perspectives,
Dr. Seema Puri, University of Delhi urged for greater reliance on India’s own scientific institutions, such as ICMR, rather than depending exclusively on foreign literature. She underscored the importance of meta-analytical research on HFSS, along with portion control and moderation, as essential strategies in the prevention of Non-Communicable Diseases (NCDs).
Dr. Swati Bhardwaj from a Public Health Organization “Resolve to Save Lives” further stressed the need to establish standardized portion sizes across food categories to better guide consumers and policymakers alike.
The third session of swasth workshop focused on the food industry’s perspective, bringing together experts from regulatory, legal, and allied sectors. Leading companies such as ITC Ltd., Marico, Nestlé India Ltd., and Jadli Foods India P Ltd, along with industry associations like FICCI, CII, PBFIA, India Honey Alliance, and IFBA shared their views and concerns regarding HFSS foods and UPF.
There was broad consensus on the need for robust clinical trials and strong scientific evidence before formulating or implementing HFSS and UPF-related policies that could significantly impact both public health and the food industry.
During the discussion at the swasth workshop industry representatives urged policymakers to consider a serve size-based regulatory model and called for a comprehensive national nutrition survey to better understand actual dietary habits and the health needs of India’s diverse population.
Associations also emphasized the importance of moving beyond emotional rhetoric to focus on the scientific and economic contributions of the Indian food processing sector. “Food processing is often unfairly criticized in public debates, while its positive contributions—such as ensuring food safety, maintaining hygiene standards, reducing food wastage, and creating employment—are frequently overlooked,” noted the participant. It was strongly advocated that future policies be grounded in rational, evidence-based frameworks that reflect the complex realities of modern food systems.
Participants also highlighted a key concern that many genuinely healthy foods, such as coconut milk, oat milk, and tofu, may fall under the UPF category despite their nutritional value, underscoring the need for greater nuance and clarity in classification systems. With the participation of over 80 in-person attendees from industry, academia, regulatory bodies, business associations, consumer forums, and start-ups, the event also saw more than 100 virtual participants joining online.
The swasth workshop event concluded with a call for balanced awareness – encouraging consumers to be informed about HFSS and UPF, without succumbing to fear or confusion. The takeaway message: “Eat consciously. Keep it simple. Avoid ‘Virrudha Aahar’ (incompatible food combinations), so that NCDs can be prevented.”
Understanding What ‘Sugar-Free’ Really Means for Your Health
Sugar-free labels are everywhere — from snacks and soft drinks to yogurts and cereals — often signaling a healthier option to consumers. But not everything that says “sugar-free” or “no added sugar” is truly free from sugar or risk. While the terms might appear similar, they carry very different meanings and can affect your health depending on your dietary needs.
Many people choose sugar-free products to manage diabetes, cut calories, or adopt a healthier lifestyle. However, the difference between “sugar-free” and “no added sugar” is more than just marketing — it’s about how much sugar and what kind is actually in your food.
Why ‘Sugar-Free’ Doesn’t Always Mean Sugar-Free
In general, a product labeled “sugar-free” usually contains less than 0.5 grams of sugar per serving. It doesn’t mean there is absolutely no sugar — naturally occurring sugars might still be present from ingredients like milk or fruit. These products often rely on sugar substitutes such as sugar alcohols (like erythritol, sorbitol) or artificial sweeteners (like sucralose or aspartame) to add sweetness without calories.
On the other hand, “no added sugar” means that no sugar or sweeteners were added during the manufacturing process. However, the product may still contain natural sugars that occur in its ingredients. A fruit juice labeled “no added sugar,” for example, might still be loaded with natural fruit sugars.
While these definitions are regulated in many parts of the world, they’re not consistent everywhere. In the U.S., the FDA enforces standards for “sugar-free” and “no added sugar” claims. In Europe, rules also apply. But in countries like Australia, the definitions may not be as clearly enforced across all food items.
One major concern with sugar-free products is the inclusion of sugar alcohols and artificial sweeteners. Sugar alcohols, like erythritol, are popular because they provide sweetness with fewer calories and are less damaging to teeth. However, recent studies suggest that excessive consumption of erythritol could be linked to a higher risk of heart attacks or strokes.
The Hidden Sugars and Sweeteners You Might Be Missing
Similarly, artificial sweeteners have long been debated. Though approved by food safety agencies, some research indicates that long-term use of these sweeteners might not help with weight control and could increase the risk of metabolic disorders such as type 2 diabetes or cardiovascular disease. While they offer the benefit of fewer calories, the potential health trade-offs may not be worth it for everyone.
Even when buying “no added sugar” items, hidden sugars can still be a concern. These products might contain ingredients like fruit concentrates, cane juice, or syrups that naturally boost sugar levels. The only way to know is to look beyond the marketing and read the Nutrition Facts label. The “Total Sugars” line will include both natural and added sugars, giving a clearer picture of what you’re really consuming.
Many people are misled by these labels and unknowingly consume more sugar than intended. For those managing conditions like dia
betes or trying to reduce sugar intake, these hidden ingredients can disrupt their dietary goals. That’s why checking ingredient lists and prioritizing whole, minimally processed foods is essential.
Choosing foods labeled “unsweetened” is often a better strategy when trying to avoid any kind of sugar. These products typically contain neither added nor artificial sweeteners and offer a cleaner option. Whole fruits, vegetables, plain dairy products, and naturally low-sugar snacks remain the safest picks for those watching their sugar intake.
As consumers become more health-conscious, understanding food labels becomes even more important. A label might sound healthy, but the details tell the real story.
Just because something says “sugar-free” or “no added sugar” doesn’t mean it’s truly free from sugar or safe for all diets. Reading labels carefully and understanding what these terms actually mean can help you make smarter, healthier choices every day.
West Bengal COVID-19 Cases Rise Again: The state of West Bengal, much like several other parts of India and the world, is witnessing a fresh surge in COVID-19 cases. As of late May 2025, health authorities have reported 11 active cases, with four new infections detected recently. The sudden rise in infections has drawn attention to a new sub-variant of the Omicron strain, known as JN.1, along with its offshoots NB.1.8.1 and LF.7. While the overall severity of the illness caused by these sub-variants remains mild, the increasing number of cases has triggered concern among health officials, epidemiologists, and the public alike.
This article aims to provide a comprehensive understanding of the current COVID-19 scenario in West Bengal. It will cover the epidemiological details, symptoms, transmission dynamics, the significance of the JN.1 variant, and the necessary preventive measures. Additionally, it will discuss the preparedness of the healthcare infrastructure, vaccination status, and lessons learned from previous waves.
West Bengal COVID-19 Cases: Current Situation
As per the official data released on May 26, 2025, West Bengal has recorded 11 active COVID-19 cases, marking an increase from previous weeks when cases had dwindled significantly. The new cases primarily emerged from Kolkata and surrounding areas such as Mograhat in South 24 Parganas, a region that experienced high infection rates during earlier waves.
A particularly notable case includes a 15-year-old boy from Rishra who was admitted to Peerless Hospital with symptoms including high fever, persistent cough, vomiting, and severe dehydration. This case is significant because it represents the first detection of SARS-CoV-2 in Peerless Hospital since September 2024, indicating that the virus is resurfacing even in regions and hospitals that had previously seen a lull.
Health officials emphasize that these new infections are being closely monitored. Most patients are exhibiting mild to moderate symptoms and are undergoing treatment in both state-run and private healthcare facilities. None of the recent patients, as per reports, have required intensive care or ventilatory support, reflecting the less severe nature of the current strains.
Understanding the JN.1 Variant and Its Sub-Lineages
The JN.1 variant is a sub-lineage of the Omicron variant, which dominated globally in earlier years due to its high transmissibility and comparatively lower severity. The emergence of JN.1 and its subvariants such as NB.1.8.1 and LF.7 has sparked interest and caution in the scientific community.
Characteristics of the JN.1 Variant
High Transmissibility: Similar to previous Omicron variants, JN.1 spreads rapidly through respiratory droplets, contact with contaminated surfaces, and close personal contact.
Mild to Moderate Symptoms: Clinical presentations predominantly resemble those of the common flu, with symptoms like fever, sore throat, dry cough, nasal congestion, and gastrointestinal issues such as diarrhea.
Potential for Underreporting: Due to mild symptoms that overlap with seasonal flu and other common illnesses, many individuals may self-medicate or neglect to get tested, which could lead to underreporting and silent spread.
Immune Escape: Early studies suggest JN.1 has some mutations that may reduce the effectiveness of neutralizing antibodies, leading to breakthrough infections in vaccinated individuals, though vaccines still provide significant protection against severe illness and hospitalization.
Comparison with Earlier Variants
While JN.1 shares several characteristics with the original Omicron variant, it differs in its genetic makeup, which might influence transmissibility and immune escape capabilities. Fortunately, there is currently no evidence suggesting increased severity or higher fatality rates compared to earlier variants.
Symptoms and Clinical Presentation
The symptoms associated with the JN.1 variant are similar to those experienced in previous Omicron waves but are generally milder than those from the Delta variant or the original strain. The most common symptoms include:
Fever (often low-grade)
Sore throat
Dry cough
Nasal congestion or runny nose
Fatigue and body aches
Gastrointestinal symptoms such as nausea, vomiting, or diarrhea in some cases
Because these symptoms closely resemble those of seasonal flu or common cold, healthcare professionals urge caution and recommend testing for anyone exhibiting these symptoms, especially if they have had recent exposure to confirmed cases or travel history to affected areas.
Public Health Response in West Bengal
In response to the resurgence, the West Bengal health authorities have ramped up surveillance and testing activities. Contact tracing efforts have been intensified in affected districts to identify and isolate positive cases quickly. Public health messages emphasizing the importance of mask-wearing, hand hygiene, and social distancing have been reinforced through various media platforms.
Testing and Contact Tracing
The state government has increased the number of COVID-19 testing centers, including rapid antigen tests and RT-PCR facilities.
Mobile testing units have been deployed to hotspots to ensure accessibility.
Contact tracing teams are actively working to identify and monitor close contacts of confirmed cases.
Healthcare Infrastructure Preparedness
Hospitals across the state, both government and private, have been alerted to expect a possible rise in cases.
Isolation wards have been prepared and are being kept ready for admission if the case numbers increase.
Medical oxygen supply and essential drugs are being stockpiled as a precaution.
Vaccination Drives
Vaccination remains a critical tool in combating COVID-19. West Bengal continues to promote vaccination campaigns targeting booster doses for eligible populations, especially vulnerable groups like the elderly and immunocompromised.
The state has achieved substantial vaccination coverage, with over 80% of the eligible population receiving at least two doses.
Booster dose drives are ongoing, with efforts to reach remote areas.
Awareness campaigns address vaccine hesitancy and misinformation.
Global Context and Comparisons
The rise of sub-variants such as JN.1 is not unique to West Bengal or India; many countries globally have reported similar strains causing localized spikes in infections. Studies from Europe and parts of North America indicate that while these variants spread quickly, the rates of hospitalization and death have not increased significantly.
Countries are adopting strategies focusing on vaccination, targeted restrictions, and protecting vulnerable populations.
Researchers worldwide continue to monitor genetic changes in the virus to predict future trends and update vaccines accordingly.
Implications for Public and Economic Life
The resurgence of COVID-19 cases, even at relatively low levels, impacts public behavior and economic activities. Schools, workplaces, and public transport services have revisited safety protocols. Some sectors are reconsidering hybrid work models to reduce crowding.
Education: Schools are encouraging parents to keep children home if symptomatic and are reinforcing mask mandates.
Workplaces: Companies are promoting remote work where feasible and emphasizing workplace hygiene.
Public Transport: Increased cleaning protocols and mask mandates are in place.
Events and Gatherings: Authorities advise caution for large public events and gatherings.
Preventive Measures and Recommendations
Health experts continue to stress the importance of following basic preventive measures:
Mask Wearing: Especially in crowded or enclosed spaces.
Hand Hygiene: Frequent handwashing or using hand sanitizers.
Physical Distancing: Maintaining distance where possible.
Testing and Isolation: Getting tested promptly if symptomatic and isolating to prevent spread.
Vaccination: Completing the full vaccination schedule including boosters.
Monitoring Symptoms: Early detection through self-monitoring and timely medical consultation.
Challenges and the Road Ahead
Challenges
Misinformation and Complacency: As the pandemic progresses, misinformation about the virus and vaccines persists, leading to complacency among some segments of the population.
Healthcare Fatigue: The prolonged pandemic has strained healthcare workers and resources, which may affect response capacity.
Virus Evolution: The virus continues to mutate, requiring constant vigilance and adaptability in public health strategies.
Opportunities
Scientific Advancements: Rapid development of vaccines and therapeutics.
Improved Surveillance: Genomic sequencing capabilities have enhanced tracking of variants.
Public Awareness: Increased knowledge about infectious disease prevention.
The recent increase in COVID-19 cases in West Bengal serves as a reminder that the pandemic is not over, and vigilance remains essential. The JN.1 variant, while highly transmissible, appears to cause mild illness for most, thanks in large part to vaccination and prior infections. Public health authorities urge citizens to remain cautious, adhere to recommended guidelines, and participate in vaccination drives to protect themselves and their communities.
Maintaining a balance between normalcy and caution will be key to managing this new wave. With collective efforts from government, healthcare workers, scientists, and the public, West Bengal can navigate this resurgence effectively and minimize the impact on health and society.
Do Follow:
Ministry of Health and Family Welfare (MoHFW) – COVID-19 Dashboard This dashboard offers real-time data on COVID-19 cases across India, including state-wise statistics for West Bengal. 🔗 https://covid19dashboard.mohfw.gov.in/
Press Information Bureau (PIB) – COVID-19 Press Releases The PIB provides official press releases and updates from the Government of India regarding COVID-19, including information on new variants like JN.1. 🔗 https://www.pib.gov.in/PressReleseDetail.aspx?PRID=1987840
Integrated Disease Surveillance Programme (IDSP) – Ministry of Health and Family Welfare IDSP monitors disease outbreaks and provides alerts and updates, including those related to COVID-19. 🔗 https://idsp.mohfw.gov.in/
Indian Council of Medical Research (ICMR) ICMR conducts and disseminates research on various health issues, including COVID-19 variants and their impact. 🔗 https://www.icmr.gov.in/
INSACOG (Indian SARS-CoV-2 Genomics Consortium) INSACOG monitors the genomic variations in SARS-CoV-2, including tracking new variants like JN.1. 🔗 https://insacog.gov.in/
Government of West Bengal – Department of Health & Family Welfare The official portal provides state-specific health advisories, updates, and resources related to COVID-19. 🔗 https://www.wbhealth.gov.in/
Press Information Bureau (PIB) – COVID-19 Updates Regular bulletins and updates on the COVID-19 situation in India, including variant tracking and health advisories. 🔗 https://pib.gov.in/PressReleasePage.aspx?PRID=1778959
New variants and sudden surges spark quiet concern across key Indian states
COVID-19 in India has taken an unexpected turn with active cases suddenly increasing to 1,009 as of May 26, 2025. Just a week ago, the number stood at only 257, indicating a sharp rise that has quietly put health authorities on alert.
Most of the new cases are being reported from Tamil Nadu, Kerala, and Maharashtra, where state officials have begun intensifying local surveillance and urging caution in public spaces. This rise, although not severe in impact yet, reflects a shift in the pandemic’s current pace in the country.
COVID-19 in India Sees Sharp Climb, Renewing Focus on Emerging Variants
Contributing to this change are two newly detected COVID-19 subvariants: NB.1.8.1 and LF.7. One case of NB.1.8.1 was identified in Tamil Nadu last month, while four cases of LF.7 emerged earlier in May. These variants have been observed in other parts of Asia as well and are being monitored globally. The World Health Organization has placed them under the “Variants Under Monitoring” category — not yet classified as dangerous, but closely tracked due to their behavior.
So far, seven new COVID-related deaths have been recorded in the past week across India. Meanwhile, 305 individuals have recovered or been discharged during the same time frame, bringing some balance to the overall numbers. Still, the rising trend has prompted renewed attention from state health departments.
Though there is no official talk of lockdowns or major restrictions, local governments are advising the use of masks in crowded places and are readying hospitals in case of further escalation. Public messaging remains calm, encouraging citizens to stay updated on vaccines, maintain hygiene, and avoid unnecessary panic.
Experts say that while this rise in cases may seem sudden, it’s not entirely surprising given how respiratory viruses tend to behave. Seasonal changes and increased mobility can often lead to localized outbreaks. What’s different this time is the unfamiliar nature of the variants and how they might evolve.
As of now, most of the infections are mild and manageable from home. Hospitalization rates remain low, and India’s high vaccination coverage continues to play a crucial role in keeping complications under control.
There’s a growing sense of watchfulness but not worry. The coming days will reveal whether this is just a short spike or something more prolonged. Health authorities are preparing quietly but firmly.
COVID-19 in India may not be in the spotlight anymore, but its return in subtle waves is a reminder to stay aware and prepared. With informed actions and timely precautions, the country can navigate this phase calmly and confidently.
The West Bengal government has banned 137 medicines to tackle the proliferation of counterfeit and substandard drugs. This article delves into the reasons behind the ban, the types of medicines affected, and the measures being implemented to ensure drug safety.
In a decisive and far-reaching step to protect public health, the West Bengal government has announced an immediate ban on 137 pharmaceutical products that have been identified as either counterfeit, substandard, or deemed unsafe for consumption. This unprecedented move reflects the growing urgency with which the state is addressing the widespread infiltration of fake and spurious medicines into the healthcare system. The ban follows comprehensive testing and inspections conducted by the state’s health department, in collaboration with national regulatory bodies such as the Central Drugs Standard Control Organisation (CDSCO), which confirmed that many of these medicines failed to meet the prescribed safety and quality benchmarks.
The implications of such a crackdown are enormous—not only in terms of public health, but also in maintaining the credibility of the state’s drug supply chain, which services a population of over 90 million. Counterfeit drugs have long plagued India’s pharmaceutical landscape, with West Bengal emerging as one of the recent hotspots for such illicit activity. From essential antibiotics and fever medications to eye drops and gastrointestinal drugs, the banned list includes a range of commonly used medicines, making the issue even more alarming for patients who rely on these drugs for everyday treatment and chronic illness management.
Health experts have praised the government’s intervention as timely and critical, especially in the aftermath of the COVID-19 pandemic, which created supply chain vulnerabilities that counterfeit drug networks have actively exploited. The pandemic not only heightened demand for certain categories of drugs but also disrupted traditional distribution channels, allowing fake suppliers to enter the market under the guise of legitimate dealers. Reports from the Bengal Chemists & Druggists Association (BCDA) suggest that there has been a staggering 47% rise in counterfeit medicine circulation in West Bengal alone since 2021.
This latest ban represents the first phase of a broader strategy being formulated by the state government to rid the pharmaceutical market of spurious products and hold accountable those responsible for manufacturing, distributing, or selling them. By taking firm legal and administrative action, West Bengal aims to send a strong message to drug cartels and illegal syndicates that public health cannot and will not be compromised for profit.
Furthermore, this move is not just about halting the supply of fake drugs—it also signals an awakening within the healthcare administration to prioritize regulatory compliance, ensure the traceability of medicines through QR codes and serialization, and boost consumer confidence in the formal healthcare infrastructure. It’s a wake-up call not only for pharmacists and distributors, but also for consumers to become more vigilant, verify drug authenticity, and report any suspected cases of counterfeit medicines to authorities.
As the ban begins to be enforced across pharmacies, hospitals, and wholesale markets in West Bengal, it sets a precedent that other Indian states might soon follow. The ripple effect of this decision is likely to be felt across the entire healthcare ecosystem, encouraging better standards, improved regulatory practices, and a renewed commitment to patient safety in India’s pharmaceutical sector.
Understanding the Ban (Expanded)
The decision by the West Bengal government to ban 137 medicines is not arbitrary—it follows a methodical, evidence-based investigation into the quality and origin of several pharmaceutical products circulating in the market. According to senior officials in the state’s Health and Family Welfare Department, these medicines were found to be either counterfeit, unapproved, expired, or manufactured in facilities that lacked proper licensing and quality control infrastructure.
The banned list comprises a wide variety of drug types, including:
Antibiotics like amoxicillin and ciprofloxacin
Painkillers such as tramadol and diclofenac combinations
Antipyretics and anti-inflammatory drugs
Gastrointestinal medications like ranitidine and omeprazole variants
Ophthalmic solutions (eye drops)
Cough syrups and antihistamines
These are not niche or rare medications but ones that feature prominently in prescriptions for routine illnesses. The sheer diversity of the drugs included in the ban reveals the deep penetration of counterfeit substances into West Bengal’s public and private healthcare systems.
The ban was formalized after quality checks were conducted at the state drug testing laboratory, supported by data from the Central Drugs Standard Control Organisation (CDSCO), which issues monthly alerts on Not of Standard Quality (NSQ) drugs. Out of the 137 medicines flagged, many had failed basic pharmacopoeial tests such as sterility, assay value, pH, and impurity profiles—standards mandated under the Drugs and Cosmetics Act, 1940.
This move is also a direct response to rising public and medical concern. Doctors across government hospitals and private clinics had been reporting repeated instances of “drug failure”—patients showing no improvement even after taking prescribed medicines. In some cases, the use of fake or substandard drugs led to severe adverse drug reactions (ADRs), extended hospital stays, and avoidable deaths.
By implementing the ban, the West Bengal government aims not only to protect patient lives but also to restore confidence in the pharmaceutical sector, which is among India’s most important economic and public service segments.
The Counterfeit Drug Crisis in West Bengal
The phenomenon of counterfeit drugs is neither new nor limited to West Bengal. However, the situation in the state has become increasingly dire in recent years, prompting urgent intervention.
Following the pandemic, drug regulatory bodies in India saw a spike in fake drug seizures. In West Bengal, the trend became alarmingly visible in 2023–2025, especially in Kolkata, North 24 Parganas, and Murshidabad. A report released by the Bengal Chemists and Druggists Association (BCDA) revealed that fake medicines accounted for nearly half of all drugs tested in surprise raids.
These counterfeit drugs often mimic the packaging of reputable brands, making it almost impossible for untrained eyes—be they pharmacists or consumers—to identify them. However, the chemical composition either lacks the active pharmaceutical ingredient (API) or contains toxic or incorrect substances, which can be deadly or ineffective.
One major incident that catalyzed state action occurred in Titagarh, where the Directorate of Drug Control unearthed a massive warehouse filled with spurious drugs worth over ₹34 lakh. The products were allegedly smuggled in bulk from Uttar Pradesh and Jharkhand, labeled under fake brand names, and distributed across various retail points in the state.
According to sources in the police department, these drug rings often operate in highly organized networks. They function across state borders and have ties with some unscrupulous suppliers, distributors, and even elements within the pharmacy trade. This raises the stakes for state governments like West Bengal, which must now not only regulate local manufacturers but also coordinate inter-state operations and surveillance mechanisms to identify supply chain vulnerabilities.
The West Bengal government’s decision to ban 137 medicines is being hailed as a long-overdue crackdown, but health experts caution that this is only the beginning of what must be a prolonged war against a deeply embedded menace.
Impact on Public Health and the Healthcare System
The proliferation of counterfeit medicines has a catastrophic impact on public health. When a patient consumes medicine, there is an inherent trust that the product is safe, scientifically tested, and effective. Counterfeit and substandard medicines break that trust—and the consequences can be fatal.
Among the gravest dangers are:
Therapeutic Failure: Patients with infections, chronic diseases, or post-operative needs who consume ineffective medications may suffer deterioration in health, prolonged illness, and relapses.
Drug Resistance: Incomplete or fake antibiotic treatments are known to cause antimicrobial resistance (AMR), which has become one of the top global health threats.
Toxic Reactions: Some counterfeit drugs contain wrong or contaminated ingredients, leading to poisoning, organ damage, and even death.
Maternal and Child Health Risks: Pregnant women and children, who require precise dosages and safe formulations, are especially vulnerable.
Economic Burden: Families spend thousands on repeated hospital visits, tests, and second-round medications due to failure of the first course, often pushing low-income households further into poverty.
The healthcare system itself is burdened when patients return to hospitals with unresolved symptoms or deteriorating conditions. This leads to increased bed occupancy, pressure on doctors, misuse of diagnostic resources, and a general erosion of faith in both government and private medical services.
Through the ban, the West Bengal government aims to halt this destructive cycle and lay the groundwork for a safer pharmaceutical landscape—one where quality, traceability, and safety are non-negotiable.
Government’s Response and Measures
Following the announcement that the West Bengal government bans 137 medicines, Chief Minister Mamata Banerjee’s administration has moved swiftly to implement supplementary measures to prevent recurrence. The Health & Family Welfare Department issued immediate instructions to all Chief Medical Officers of Health (CMOHs), Drug Inspectors, and hospital superintendents to remove the banned drugs from their inventories and ensure compliance within a 72-hour timeframe.
At the press briefing in Nabanna, the state’s Chief Secretary outlined a five-point action plan aimed at tackling the counterfeit drug menace:
Statewide Inventory Audit: All hospitals and pharmacies—public and private—will undergo rigorous inventory checks, with random sampling of stocked medicines.
Pharmacy Compliance Check: Chemists must now maintain digital records of suppliers and submit quarterly reports on medicine purchases to the State Drug Control Directorate.
Task Force Creation: A joint enforcement task force comprising health officials, local police, and excise officers will monitor medicine movement across border districts.
Public Helpline & Reporting Mechanism: A 24/7 helpline is being set up where citizens can report suspicious drugs or illegal sales.
Training for Pharmacists: The state will organize capacity-building workshops to help pharmacists identify fake packaging, expired drugs, and verify QR codes linked to batch-level information.
The government is also coordinating with the National Pharmaceutical Pricing Authority (NPPA) and CDSCO to ensure that similar drugs from other states don’t leak into West Bengal’s supply chain.
In an unprecedented step, the West Bengal Drug Control Directorate has partnered with IIT-Kharagpur to develop a blockchain-based tracking system to enhance traceability of medicine batches. The goal is to make every drug packet traceable back to its origin through a QR-code verification system accessible via mobile apps.
West Bengal Government Bans 137 Medicines: Challenges Ahead
While the government’s efforts are commendable, experts warn that enforcement will face substantial obstacles. The pharmaceutical distribution network in India, particularly in populous states like West Bengal, is highly fragmented. With thousands of wholesalers and retailers spread across rural and urban zones, maintaining uniform vigilance is a daunting task.
Some key challenges include:
Lack of Trained Personnel: The number of qualified drug inspectors is far below what is required for real-time, statewide surveillance.
Deep-Rooted Corruption: In some instances, low-level corruption and bribery within inspection systems allow non-compliant traders to operate freely.
Low Public Awareness: Many patients in rural areas are unaware of the risks of fake drugs and do not verify the source or expiry dates.
Online Pharmacy Loopholes: E-pharmacy platforms, while convenient, often escape strict scrutiny, enabling counterfeit sellers to infiltrate with fake listings.
The West Bengal government has acknowledged these systemic hurdles and plans to submit a proposal to the Union Ministry of Health requesting financial and logistical support to bolster inspection and training mechanisms.
Legal and Pharmaceutical Industry Reaction
The legal framework supporting drug regulation in India stems from the Drugs and Cosmetics Act, 1940, and the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Violation of quality standards under these laws can lead to fines, license cancellation, and imprisonment.
In response to the news that the West Bengal government bans 137 medicines, several FIRs have already been lodged against pharmaceutical companies and distributors. A few major wholesale dealers in Burra Bazar and Barasat have had their licenses suspended, pending further investigation. Police raids are also underway in Cooch Behar, Howrah, and Nadia.
The pharmaceutical industry, however, has issued mixed responses. While responsible manufacturers welcomed the crackdown, citing it as a necessary step to cleanse the market, some smaller traders expressed concern over lack of prior warning and potential disruption to business. The Bengal Chemists and Druggists Association (BCDA) has asked for a list of approved substitutes to help pharmacies serve patients without delay.
Meanwhile, legal experts argue that the state must follow due process to avoid arbitrary seizures. Advocate Arindam Das, a Kolkata-based pharma law expert, stated,
“The state is absolutely justified in banning harmful drugs. However, transparency in testing and ensuring manufacturers can appeal findings is essential to prevent misuse of the ban mechanism.”
National Implications and Ripple Effect
The announcement that the West Bengal government bans 137 medicines could have a far-reaching impact beyond the borders of the state. Public health experts say that other Indian states may follow suit, especially those grappling with similar counterfeit drug problems, such as Uttar Pradesh, Bihar, and Madhya Pradesh.
The Union Health Ministry has taken note of the action and has reportedly asked the Central Drugs Laboratory in Kolkata to cross-check the banned list and issue advisories to other states. If these medicines are found circulating across states, a national-level ban or recall may follow.
Additionally, this move could accelerate the central government’s push toward a nationwide digital drug-tracking system. Under the “Track and Trace” initiative, each strip or vial of medicine will carry a unique code allowing regulators and consumers to verify its authenticity from manufacturing to retail.
Internationally, the step has been welcomed by global health bodies. Representatives from the World Health Organization (WHO) and Médecins Sans Frontières (MSF) have lauded the state’s commitment to tackling fake drugs, which are a menace not only in India but across developing nations.
The West Bengal government’s ban on 137 medicines marks a watershed moment in India’s fight against counterfeit and substandard drugs. It sends a strong message that public health takes precedence over profiteering, and the safety of every patient must be non-negotiable.
However, this decisive move must be accompanied by consistent enforcement, robust monitoring, and proactive public engagement. If implemented efficiently, this crackdown could serve as a template for other states and even the Union government to adopt stronger drug regulation frameworks.
At its core, this action isn’t just about banning a few medicines—it’s about rebuilding public trust in the healthcare system, holding manufacturers accountable, and preventing future tragedies caused by fake drugs.
As West Bengal tightens its grip on pharmaceutical safety, the rest of India—and indeed the world—will be watching closely.
For years, people believed that memory loss and dementia were simply caused by aging and dying brain cells. But now, experts say something else may be going on—chronic inflammation in the brain. This kind of inflammation builds up slowly over time and creates what researchers call a “fog,” which affects how the brain works. The good news? This fog can be cleared.
The root of the problem is something called the blood-brain barrier. This barrier protects the brain by keeping harmful substances in the blood from getting into the brain. But in many older people, this barrier becomes leaky. When that happens, a blood protein called albumin enters the brain and causes inflammation.
New research shows brain inflammation—not just aging—may be the real cause of memory loss
In experiments, scientists injected this protein into the brains of young mice. The result? Their brains started acting old. They had trouble learning, showed signs of stress, and were more likely to have seizures. But when researchers gave the mice special drugs that blocked the harmful effects of this protein, the mice’s brain function improved quickly. They learned faster, had fewer memory problems, and their brains showed less inflammation.
One drug called IPW, created by a chemist in California, worked especially well. It blocks a specific brain receptor that causes inflammation. When older mice were given this drug, their brain activity looked young again. They even performed better in tasks like finding their way through a maze.
These findings suggest that drugs targeting brain inflammation could help treat or even reverse dementia. The scientists also found ways to spot brain inflammation early—through special MRI and brain wave tests. This could help doctors know who would benefit most from the treatment.
Even in human brains, the researchers found signs of the same problems—leaky barriers, inflammation, and high levels of the same protein. This means the findings from mice could be useful for treating people with conditions like Alzheimer’s disease and memory loss linked to age.
Now, the team is working to develop these drugs for human use. They hope to help older adults who show signs of brain inflammation, especially those with memory loss or early dementia. The goal is to stop or even reverse the brain changes that come with aging.
Drugs that reduce brain inflammation by targeting the TGF-β pathway may hold the key to reversing age-related dementia. With further development, this discovery could change how we treat aging brains, bringing new life and clarity to millions living with cognitive decline.
Dr. Satyen Panda, Executive Director (R&D) and Advisor (QA, FSSAI), addressed the risks associated with HFSS (High in Fat, Salt, and Sugar) and ultra-processed foods (UPFs). He noted that adulteration is widespread in many processed items and emphasized the need for a balanced and scientific approach to combat this growing concern effectively.
Dr. Seema Puri, University of Delhi urged for greater reliance on India’s own scientific institutions, such as ICMR, rather than depending exclusively on foreign literature. She underscored the importance of meta-analytical research on HFSS, along with portion control and moderation, as essential strategies in the prevention of Non-Communicable Diseases (NCDs).
.